Physician profile
Swarna Varma
NPI 1073599445
$520,354.60
in general payments reported to CMS, 2019-2025
41 companies · $67K in 2025
The $67K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $87K · 2021: $36K · 2022: $70K · 2023: $31K · 2024: $40K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Travel and Lodging: $22K · Food and Beverage: $5,818 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109,371.00 |
| Travel and Lodging | $22,161.12 |
| Food and Beverage | $5,818.46 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $355,257.73 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $49,104.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $28,803.31 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $23,566.20 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $23,226.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $12,751.91 | 2019-2021 | |
| Abbvie INC. | $9,969.06 | 2019-2025 | Synthroid, Ubrelvy |
| Esperion Therapeutics, INC. | $5,741.41 | 2021-2024 | Nexletol |
| Abbott Laboratories | $3,822.09 | 2019-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $1,795.79 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $1,522.01 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $1,476.02 | 2019-2025 | Unithroid |
| Medtronic, INC. | $954.54 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Becton, Dickinson and Company | $374.06 | 2019-2022 | |
| Novo Nordisk INC | $330.64 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $310.44 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $180.73 | 2019-2025 | Tepezza, Repatha, Repatha |
| Kowa Pharmaceuticals America, INC. | $172.92 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $97.32 | 2021-2025 | Gvoke Hypopen |
| Genzyme Corporation | $90.00 | 2019 | |
| Embecta Corp. | $84.94 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascendis Pharma Endocrinology INC | $78.14 | 2025 | Yorvipath |
| Corcept Therapeutics | $70.54 | 2020-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.36 | 2020-2021 | |
| Insulet Corporation | $52.10 | 2019-2024 | Omnipod |
| Neurocrine Biosciences, INC. | $51.37 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.11 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $42.34 | 2024-2025 | Strensiq |
| Pfizer INC. | $40.46 | 2019-2023 | |
| Beta Bionics, INC. | $33.80 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $31.85 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $31.12 | 2021 | |
| Zealand Pharma US, INC. | $30.58 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $29.61 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $19.50 | 2022 | |
| Sequel Med Tech, LLC | $17.31 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $17.22 | 2021 | |
| Antares Pharma, INC. | $16.60 | 2024 | Xyosted |
| Grt US Holding, INC. | $16.47 | 2021 | |
| Shield Therapeutics INC | $14.58 | 2023 | Accrufer |
| Lifescan, INC. | $13.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swarna Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.